These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36827953)

  • 1. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
    Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
    Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
    Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
    J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
    Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
    Cheng L; Zhou S; Zhou S; Shi K; Cheng Y; Cai MC; Ye K; Lin L; Zhang Z; Jia C; Xiang H; Zang J; Zhang M; Yin X; Li Y; Di W; Zhuang G; Tan L
    Cancer Res; 2022 Oct; 82(19):3588-3602. PubMed ID: 35857807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current progress and novel strategies that target CDK12 for drug discovery.
    Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
    Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
    Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
    J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
    Tadesse S; Duckett DR; Monastyrskyi A
    Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
    Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
    Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation.
    Schmitz M; Kaltheuner IH; Anand K; Düster R; Moecking J; Monastyrskyi A; Duckett DR; Roush WR; Geyer M
    J Biol Chem; 2024 Jan; 300(1):105501. PubMed ID: 38016516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational studies to explore inhibitors against the cyclin-dependent kinase 12/13 enzyme: an
    Ghosh A; Jha PC; Manhas A
    J Biomol Struct Dyn; 2024; 42(21):11997-12010. PubMed ID: 37817503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
    Wu W; Yu S; Yu X
    Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
    Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and resistance mechanism of a selective CDK12 degrader.
    Jiang B; Gao Y; Che J; Lu W; Kaltheuner IH; Dries R; Kalocsay M; Berberich MJ; Jiang J; You I; Kwiatkowski N; Riching KM; Daniels DL; Sorger PK; Geyer M; Zhang T; Gray NS
    Nat Chem Biol; 2021 Jun; 17(6):675-683. PubMed ID: 33753926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma.
    Houles T; Boucher J; Lavoie G; MacLeod G; Lin S; Angers S; Roux PP
    Cell Death Discov; 2023 Dec; 9(1):459. PubMed ID: 38104154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.